Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001887572 | SCV002160052 | uncertain significance | Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency | 2022-07-29 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 501 of the MTO1 protein (p.Tyr501His). This variant is present in population databases (rs143378575, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with MTO1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1397124). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004651792 | SCV005146676 | uncertain significance | Inborn genetic diseases | 2024-05-15 | criteria provided, single submitter | clinical testing | The c.1621T>C (p.Y541H) alteration is located in exon 10 (coding exon 10) of the MTO1 gene. This alteration results from a T to C substitution at nucleotide position 1621, causing the tyrosine (Y) at amino acid position 541 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |